Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
Elexacaftor-tezacaftor-ivacaftor (ETI) therapy is shown to improve the health of individuals with cystic fibrosis (CF) who have the F508del variant. There are in vitro studies showing benefit with ETI for select rare CF variants. Limited data exists on the use of ETI in individuals with rare CF vari...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2023-01-01
|
| Seri Bilgileri: | Respiratory Medicine Case Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2213007123001338 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|